{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:56:14Z","timestamp":1787738174376,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1497,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/mt.2012.56","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T13:49:10Z","timestamp":1340718550000},"page":"1664-1675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12"],"prefix":"10.1016","volume":"20","author":[{"given":"Jos\u00e9 I","family":"Quetglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Dubrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaione","family":"Bezunartea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hervas-Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Smerdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2012.56_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mt.2012.56_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/jnci\/87.8.581","article-title":"Inhibition of angiogenesis in vivo by interleukin 12","volume":"87","author":"Voest","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2012.56_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.gt.3301957","article-title":"Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis","volume":"10","author":"Mazzolini","year":"2003","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2012.56_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.virusres.2010.07.027","article-title":"Alphavirus vectors for cancer therapy","volume":"153","author":"Quetglas","year":"2010","journal-title":"Virus Res"},{"key":"10.1038\/mt.2012.56_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/jhep.2001.20796","article-title":"Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12","volume":"33","author":"Barajas","year":"2001","journal-title":"Hepatology"},{"key":"10.1038\/mt.2012.56_bib6","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.4049\/jimmunol.154.12.6466","article-title":"Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector","volume":"154","author":"Tahara","year":"1995","journal-title":"J Immunol"},{"key":"10.1038\/mt.2012.56_bib7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2012.56_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/hum.2005.16.91","article-title":"Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma","volume":"16","author":"Triozzi","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2012.56_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1471-4906(00)01824-X","article-title":"IL-12 gene therapy for cancer: in synergy with other immunotherapies","volume":"22","author":"Melero","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1038\/mt.2012.56_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymthe.2005.02.011","article-title":"Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas","volume":"12","author":"Rodriguez-Madoz","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.56_bib11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/0008-5472.CAN-05-0877","article-title":"Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector","volume":"66","author":"Guan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2012.56_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/10548","article-title":"Cancer therapy using a self-replicating RNA vaccine","volume":"5","author":"Ying","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mt.2012.56_bib13","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","article-title":"A new generation of animal cell expression vectors based on the Semliki Forest virus replicon","volume":"9","author":"Liljestr\u00f6m","year":"1991","journal-title":"Biotechnology (NY)"},{"key":"10.1038\/mt.2012.56_bib14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/sj.gt.3302561","article-title":"Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12","volume":"12","author":"Chikkanna-Gowda","year":"2005","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2012.56_bib15","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.3171\/foc.2000.9.6.8","article-title":"Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12","volume":"9","author":"Yamanaka","year":"2000","journal-title":"Neurosurg Focus"},{"key":"10.1038\/mt.2012.56_bib16","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1128\/JVI.01597-09","article-title":"Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma","volume":"83","author":"Rodriguez-Madoz","year":"2009","journal-title":"J Virol"},{"key":"10.1038\/mt.2012.56_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med"},{"key":"10.1038\/mt.2012.56_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nm0402-343","article-title":"Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB","volume":"8","author":"Ye","year":"2002","journal-title":"Nat Med"},{"key":"10.1038\/mt.2012.56_bib19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4049\/jimmunol.150.3.771","article-title":"Inducible T cell antigen 4-1BB. Analysis of expression and function","volume":"150","author":"Pollok","year":"1993","journal-title":"J Immunol"},{"key":"10.1038\/mt.2012.56_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/cimm.1998.1396","article-title":"NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies","volume":"190","author":"Melero","year":"1998","journal-title":"Cell Immunol"},{"key":"10.1038\/mt.2012.56_bib21","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.4049\/jimmunol.0800459","article-title":"4-1BB functions as a survival factor in dendritic cells","volume":"182","author":"Choi","year":"2009","journal-title":"J Immunol"},{"key":"10.1038\/mt.2012.56_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/0008-5472.CAN-10-1733","article-title":"Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes","volume":"71","author":"Palaz\u00f3n","year":"2011","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2012.56_bib23","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1158\/1078-0432.CCR-08-0285","article-title":"Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma","volume":"14","author":"Murillo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2012.56_bib24","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2010-08-301945","article-title":"CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies","volume":"117","author":"Kohrt","year":"2011","journal-title":"Blood"},{"key":"10.1038\/mt.2012.56_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.seminoncol.2010.09.008","article-title":"Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies","volume":"37","author":"Ascierto","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1038\/mt.2012.56_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/mthe.2000.0086","article-title":"Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation","volume":"2","author":"Chen","year":"2000","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.56_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ijc.11696","article-title":"NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation","volume":"109","author":"Xu","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2012.56_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jnci\/92.11.931","article-title":"Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model","volume":"92","author":"Martinet","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2012.56_bib29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/sj.gt.3300841","article-title":"Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography","volume":"6","author":"Asselin-Paturel","year":"1999","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2012.56_bib30","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2012.56_bib31","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1158\/0008-5472.CAN-07-0321","article-title":"Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system","volume":"67","author":"Berraondo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2012.56_bib32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.190.10.1535","article-title":"Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy","volume":"190","author":"Mittler","year":"1999","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2012.56_bib33","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4049\/jimmunol.175.2.884","article-title":"Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling","volume":"175","author":"Sun","year":"2005","journal-title":"J Immunol"},{"key":"10.1038\/mt.2012.56_bib34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1349-7006.2007.00529.x","article-title":"Combination antibody-based cancer immunotherapy","volume":"98","author":"Takeda","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1038\/mt.2012.56_bib35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1038\/mt.2012.56_bib36","series-title":"F. Ausubel","first-page":"16.20.11","article-title":"Expression of proteins using Semliki Forest virus vectors. Current Protocols in Molecular Biology","author":"Liljestr\u00f6m","year":"2009"},{"key":"10.1038\/mt.2012.56_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2012.56_bib38","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00262-010-0846-9","article-title":"Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ","volume":"59","author":"Dubrot","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mt.2012.56_bib39","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/eji.200838958","article-title":"In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb","volume":"39","author":"Murillo","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1038\/mt.2012.56_bib40","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.4049\/jimmunol.1004122","article-title":"Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses","volume":"186","author":"Soderquest","year":"2011","journal-title":"J Immunol"},{"key":"10.1038\/mt.2012.56_bib41","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/sj.mt.6300274","article-title":"Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration","volume":"15","author":"Rodriguez-Madoz","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.56_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/gt.2011.99","article-title":"A Semliki Forest virus vector engineered to express IFNa induces efficient elimination of established tumors","volume":"19","author":"Quetglas","year":"2012","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2012.56_bib43","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JVI.73.2.1092-1098.1999","article-title":"Two-helper RNA system for production of recombinant Semliki forest virus particles","volume":"73","author":"Smerdou","year":"1999","journal-title":"J Virol"},{"issue":"Pt 5","key":"10.1038\/mt.2012.56_bib44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1099\/0022-1317-80-5-1189","article-title":"Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge","volume":"80","author":"Fleeton","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1038\/mt.2012.56_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1083\/jcb.116.2.349","article-title":"Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry","volume":"116","author":"Salminen","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1038\/mt.2012.56_bib46","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.vaccine.2004.09.009","article-title":"Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex","volume":"23","author":"Garz\u00f3n","year":"2005","journal-title":"Vaccine"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161632158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161632158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T21:36:06Z","timestamp":1734557766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161632158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S152500161632158X"],"URL":"https:\/\/doi.org\/10.1038\/mt.2012.56","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2012.56","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}